Apolipoprotein A-I anti-tumor activity targets cancer cell metabolism.

apolipoprotein A-I cancer cholesterol de novo serine synthesis pathway mevalonate pathway

Journal

Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965

Informations de publication

Date de publication:
12 May 2020
Historique:
received: 07 12 2019
accepted: 10 04 2020
entrez: 2 6 2020
pubmed: 2 6 2020
medline: 2 6 2020
Statut: epublish

Résumé

Previously, we reported apolipoprotein A-I (apoA-I), the major protein component of high-density lipoprotein (HDL), has potent anti-melanoma activity. We used DNA microarray and bioinformatics to interrogate gene expression profiles of tumors from apoA-I expressing (A-I Tg

Identifiants

pubmed: 32477466
doi: 10.18632/oncotarget.27590
pii: 27590
pmc: PMC7233810
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1777-1796

Subventions

Organisme : NHLBI NIH HHS
ID : P01 HL076491
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL128300
Pays : United States

Déclaration de conflit d'intérêts

CONFLICTS OF INTEREST Dr. Hazen reports being named as co-inventor on pending and issued patents held by the Cleveland Clinic relating to cardiovascular diagnostics and therapeutics. Dr. Hazen also reports being a paid consultant for P&G, having received research funds from P&G and Roche Diagnostics, and being eligible to receive royalty payments for inventions or discoveries related to cardiovascular diagnostics or therapeutics from Cleveland HeartLab and P&G. All remaining authors declare that they have no conflicts of interest with the contents of this article.

Références

Clin Cancer Res. 2010 Mar 1;16(5):1577-86
pubmed: 20179230
Front Immunol. 2013 Mar 13;4:62
pubmed: 23493799
FASEB J. 2005 Sep;19(11):1513-5
pubmed: 15990392
Nat Rev Cancer. 2013 Aug;13(8):572-83
pubmed: 23822983
Expert Opin Drug Saf. 2010 Jul;9(4):603-21
pubmed: 20377474
Cell. 2019 Jan 24;176(3):564-580.e19
pubmed: 30580964
PLoS One. 2010 Feb 03;5(2):e9043
pubmed: 20140259
Nat Rev Urol. 2017 Feb;14(2):107-119
pubmed: 27779230
J Transl Med. 2010 Mar 19;8:27
pubmed: 20302635
Nat Rev Cancer. 2016 Nov;16(11):718-731
pubmed: 27562463
Cell Metab. 2019 Jun 4;29(6):1410-1421.e4
pubmed: 30905671
Cancer Epidemiol Biomarkers Prev. 2015 May;24(5):833-41
pubmed: 25934831
Front Oncol. 2018 Sep 20;8:394
pubmed: 30298120
Oncotarget. 2016 Jul 5;7(27):42208-42215
pubmed: 27283991
Cell. 2008 Sep 5;134(5):703-7
pubmed: 18775299
Nat Rev Cancer. 2011 Oct 24;11(11):775-91
pubmed: 22020205
J Am Coll Cardiol. 2010 Jun 22;55(25):2846-54
pubmed: 20579542
Drug Resist Updat. 2016 Mar;25:13-25
pubmed: 27155373
N Engl J Med. 2011 Jan 13;364(2):127-35
pubmed: 21226578
Semin Cell Dev Biol. 2012 Jun;23(4):362-9
pubmed: 22349059
Lancet. 2002 Aug 24;360(9333):587-91
pubmed: 12241928
J Natl Cancer Inst. 2006 Apr 5;98(7):472-82
pubmed: 16595783
Cell. 2012 Jan 20;148(1-2):244-58
pubmed: 22265415
J Transl Med. 2007 Apr 23;5:20
pubmed: 17451606
Oncogene. 2012 Nov 29;31(48):4967-78
pubmed: 22310279
Cancer Res. 2016 Apr 15;76(8):2063-70
pubmed: 27197250
Cell. 2011 Nov 11;147(4):759-72
pubmed: 22078877
Clin Cancer Res. 2005 Oct 15;11(20):7234-42
pubmed: 16243793
Drug Discov Today. 2012 Mar;17(5-6):232-41
pubmed: 22207221
Cancer Treat Rev. 2017 Jan;52:105-116
pubmed: 27992843
Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):E89-98
pubmed: 24367099
Nat Med. 2012 Oct;18(10):1511-7
pubmed: 23001183
Cancer Res. 2007 Apr 1;67(7):3450-60
pubmed: 17409456
J Lipid Res. 2009 Apr;50 Suppl:S195-200
pubmed: 19033213
BMC Med Genomics. 2008 Apr 28;1:13
pubmed: 18442402
Cancer Epidemiol. 2016 Dec;45:71-81
pubmed: 27750068
Nature. 2000 Aug 3;406(6795):532-5
pubmed: 10952316
Proc Natl Acad Sci U S A. 2005 Apr 26;102(17):6092-7
pubmed: 15833814
Histopathology. 2016 Jul;69(1):63-71
pubmed: 26619071
Cell Cycle. 2008 Jun 15;7(12):1851-5
pubmed: 18583930
Nature. 2000 Aug 3;406(6795):536-40
pubmed: 10952317
PLoS One. 2015 Dec 07;10(12):e0144241
pubmed: 26640950
Nat Genet. 2011 Jul 31;43(9):869-74
pubmed: 21804546
J Invest Dermatol. 2009 Jul;129(7):1666-74
pubmed: 19131946
Oncogene. 2008 Mar 6;27(11):1562-71
pubmed: 17873905
Science. 2009 May 22;324(5930):1029-33
pubmed: 19460998
Oncogene. 2003 May 19;22(20):3076-80
pubmed: 12789283
Drug Discov Today. 2019 Apr;24(4):1059-1065
pubmed: 30878563
Biochim Biophys Acta. 2012 Aug;1826(1):89-102
pubmed: 22503822
Chem Biol. 2012 Sep 21;19(9):1084-5
pubmed: 22999876
N Engl J Med. 2012 Nov 8;367(19):1792-802
pubmed: 23134381
J Neurooncol. 2013 Feb;111(3):245-55
pubmed: 23229761
Oncotarget. 2016 Jun 7;7(23):34507-19
pubmed: 27120788
Oncogene. 2016 Apr 28;35(17):2166-77
pubmed: 26279295
Melanoma Res. 2009 Apr;19(2):69-74
pubmed: 19276863
Nat Cell Biol. 2014 Apr;16(4):357-66
pubmed: 24658687
Trends Cell Biol. 2016 Apr;26(4):289-299
pubmed: 26750334
Drug Deliv Transl Res. 2013 Jun;3(3):224-34
pubmed: 25788131
Genes Dev. 2012 Jun 15;26(12):1268-86
pubmed: 22713868
J Invest Dermatol. 2009 Jul;129(7):1740-51
pubmed: 19212343
Lancet. 2015 Mar 28;385(9974):1182
pubmed: 25845793
PLoS One. 2011;6(6):e20494
pubmed: 21698147
Int J Cancer. 2017 Feb 15;140(4):747-755
pubmed: 27616679
Cancer Cell. 2011 Jul 12;20(1):79-91
pubmed: 21741598
J Invest Dermatol. 2010 Aug;130(8):2062-70
pubmed: 20357817
Cancer Res. 2004 Aug 1;64(15):5270-82
pubmed: 15289333
Matrix Biol. 2015 May-Jul;44-46:77-85
pubmed: 25636539
Curr Pharm Des. 2013;19(18):3210-4
pubmed: 23151139
Cell Rep. 2013 May 30;3(5):1663-77
pubmed: 23684612
J Biol Chem. 2013 Jul 19;288(29):21237-52
pubmed: 23720750
Int J Cancer. 2016 Sep 15;139(6):1281-8
pubmed: 27176735
Oncotarget. 2015 Dec 15;6(40):42988-3004
pubmed: 26472026
Clin Exp Metastasis. 2010 Oct;27(7):529-38
pubmed: 20632074
Nature. 2011 Aug 18;476(7360):346-50
pubmed: 21760589
Curr Cancer Drug Targets. 2006 Feb;6(1):15-37
pubmed: 16475974
J Skin Cancer. 2011;2011:858425
pubmed: 22007306
J Pharm Pharmacol. 2017 Jun;69(6):613-624
pubmed: 28271498
J Clin Oncol. 2004 Jun 15;22(12):2388-94
pubmed: 15197200
Cancer Lett. 2015 Jan 28;356(2 Pt A):309-14
pubmed: 24125862
Oncologist. 2006 Mar;11(3):306-15
pubmed: 16549815
PLoS One. 2010 Mar 12;5(3):e9685
pubmed: 20300190

Auteurs

Maryam Zamanian-Daryoush (M)

Department of Cardiovascular & Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.

Daniel J Lindner (DJ)

Taussig Cancer Institute, Cleveland Clinic, Cleveland Clinic, Cleveland, OH 44195, USA.

Jennifer Buffa (J)

Department of Cardiovascular & Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.

Banu Gopalan (B)

Yorg Corporation, Plano, TX 75093, USA.

Jie Na (J)

Department of Health Science Research, Mayo Clinic, Rochester, MN 55905, USA.

Stanley L Hazen (SL)

Department of Cardiovascular & Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH 44195, USA.

Joseph A DiDonato (JA)

Department of Cardiovascular & Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.

Classifications MeSH